Fig. 2: LRRK2 and pS1292-LRRK2 in urinary EVs of iPD subjects and PD-manifesting and non-PD-manifesting LRRK2 carriers compared to healthy controls. | npj Parkinson's Disease

Fig. 2: LRRK2 and pS1292-LRRK2 in urinary EVs of iPD subjects and PD-manifesting and non-PD-manifesting LRRK2 carriers compared to healthy controls.

From: Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson’s disease and pharmacodynamic biomarkers

Fig. 2: LRRK2 and pS1292-LRRK2 in urinary EVs of iPD subjects and PD-manifesting and non-PD-manifesting LRRK2 carriers compared to healthy controls.

Urine samples for this study were obtained from the LRRK2 cohort consortium as described in materials and methods, and the clinical characteristics of this cohort are given in Table 1. Urinary EVs were isolated for subjects’ urine samples as described in materials and methods and total-LRRK2 (a), total LRRK2 normalized to TSG101 (b), TSG101 (c), pS1292-LRRK2 (d), pS1292-LRRK2 normalized to TSG101 (e) and the rate of LRRK2 phosphorylation at S1292 (f) were determined using western blotting (quadruplicate measures per sample). Direct values and ratios of values were normalized to the ‘pool’ calibrator (Supplementary Fig. 1). Note that the values of phosphorylation ‘rate’ are indicative of the proportion of protein that is phosphorylated at the given site, see materials and methods. Results are depicted here in the form of histograms. Significant differences were tested via the Kruskal-Wallis test, using the healthy control group as control. Error bars represent standard error of the mean (s.e.m.). *P < 0,05; **P < 0,01, ***P < 0,001, ***P < 0,0001.

Back to article page